Antihyperglycemic effect of equol, a daidzein derivative, in cultured L6 myocytes and ob/ob mice

Molecular Nutrition and Food Research

Volumn 58, Issue 2, 2014, Pages 267-277

  Cheong, Sun Hee ^a,b   Furuhashi, Keisuke ^a   Ito, Katsuki ^a   Nagaoka, Masato ^a   Yonezawa, Takayuki ^c   Miura, Yutaka ^a   Yagasaki, Kazumi ^a,c  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

AMPK; Equol; Glucose transporter 4; Glucose uptake; L6 myocytes

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; CCL2 PROTEIN, MOUSE; CHOLESTEROL; EQUOL; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SLC2A4 PROTEIN, MOUSE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AMPK; ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; CELL LINE; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; L6 MYOCYTES; LIPID METABOLISM; MALE; METABOLISM; MOUSE; MOUSE MUTANT; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHORYLATION; RAT; SKELETAL MUSCLE;

AMPK; EQUOL; GLUCOSE TRANSPORTER 4; GLUCOSE UPTAKE; L6 MYOCYTES;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; CELL LINE; CHEMOKINE CCL2; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; EQUOL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLE CELLS; MUSCLE FIBERS, SKELETAL; PHOSPHORYLATION; RATS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893391990     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300272     Document Type: Article

References (44)

1. Yki-Jarvinen, H., Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 1994, 343, 91-95.
2. Hill, M.-J., Metcalfe, D., Mcternan, P.-G., Obesity and diabetes: lipids "nowhere to run to". Clin. Sci. 2009, 116, 113-123.
3. Fadini, G.-P., Miorin, M., Facco, M., Bonamico, S. et al., Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2005, 45, 1449-1457.
4. Dohm, G.-L., Tapscott, E.-B., Pories, W.-J., Dabbs, D.-J. et al., An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J. Clin. Invest. 1988, 82, 486-494.
5. DeFronzo, R.-A., Bonadonna, R.-C., Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992, 15, 318-368.
6. Winder, W.-W., Hardie, D.-G., AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 1999, 277, E1-E10.
7. Mu, J., Brozinick, J.-T., Jr., Valladares, O., Bucan, M. et al., A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell. 2001, 7, 1085-1094.
8. Gibbs, E.-M., Stock, J.-L., McCoid, S.-C., Stukenbrok, H.-A. et al., Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J. Clin. Invest. 1995, 95, 1512-1518.
9. He, L., Sabet, A., Djedjos, S., Miller, R. et al., Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009, 137, 635-646.
10. Kurosaki, E., Nakano, R., Momose, K., Shimaya, A. et al., Hypoglycemic agent YM440 suppresses hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. Eur. J. Pharmacol. 2003, 468, 151-158.
11. Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E. et al., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120, 2355-2369.
12. Rowland, I.-R., Wiseman, H., Sanders, T.-A., Adlercreutz, H. et al., Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr. Cancer. 2000, 36, 27-32.
13. Lampe, J. W. Is equol the key to the efficacy of soy foods? Am. J. Clin. Nutr. 2009, 89, 1664S-1667S.
14. Matthies, A., Clavel, T., Gütschow, M., Engst, W., Haller, D., Blaut, M., Braune, A. Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine. Appl. Environ. Microbiol. 2008, 74, 4847-4852.
15. Matthies, A., Loh, G., Blaut, M., Braune, A. Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats. J. Nutr. 2012, 142, 40-46.
16. Setchell, K.-D., Cole, S.-J., Method of defining equol-producer status and its frequency among vegetarians. J. Nutr. 2006, 136, 2188-2193.
17. Ishiwata, N., Melby, M.-K., Mizuno, S., Watanabe, S., New equol supplement for relieving menopausal symptoms: randomized, placebo controlled trial of Japanese women. Menopause 2009, 16, 141-148.
18. Jackman, K.-A., Woodman, O.-L., Sobey, C.-G., Isoflavones, equol and cardiovascular disease: pharmacological and therapeutic insights. Curr. Med. Chem. 2007, 14, 2824-2830.
19. Mizunuma, H., Kanazawa, K., Ogura, S., Otsuka, S. et al., Anticarcinogenic effects of isoflavones may be mediated by genistein in mouse mammary tumor virus-induced breast cancer. Oncology 2002, 62, 78-84.
20. Lund, T.-D., Munson, D.-J., Haldy, M.-E., Setchell, K.-D. et al., Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol. Reprod. 2004, 70, 1188-1195.
21. Rufer, C.-E., Kulling, S.-E., Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J. Agric. Food. Chem. 2006, 54, 2926-2931.
22. Yagasaki, K., Morisaki, N., Kitahara, Y., Miura, A. et al., Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in L6 myotubes. Cytotechnology 2003, 43, 97-103.
23. Kawano, A., Nakamura, H., Hata, S., Minakawa, M. et al., Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16, 437-443.
24. Nishiumi, S., Ashida, H., Rapid preparation of a plasma membrane fraction from adipocytes and muscle cells: application to detection of translocated glucose transporter 4 on the plasma membrane. Biosci. Biotechnol. Biochem. 2007, 71, 2342-2346.
25. Minakawa, M., Miura, Y., Yagasaki, K. Piceatannol, a resveratrol derivative, promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and suppresses blood glucose levels in type 2 diabetic model db/db mice. Biochem. Biophys. Res. Commun. 2012, 422, 469-475.
26. Adlercreutz, H., Mazur, W., Phyto-oestrogens and western diseases. Ann. Med. 1997, 29, 95-120.
27. Tham, D.-M., Gardner, C.-D., Haskell, W.-L., Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 1998, 83, 2223-2235.
28. Velasquez, M.-T., Bhathena, S.-J., Dietary phytoestrogens: a possible role in renal disease protection. Am. J. Kidney Dis. 2001, 37, 1056-1068.
29. Setchell, K.-D., Brown, N.-M., Lydeking-Olsen, E., The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 2002, 132, 3577-3584.
30. Harris, R.-B., Zhou, J., Jr., Redmann, S.-M., Smagin, G.-N. et al., A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. Endocrinology 1998, 139, 8-19.
31. Abiru, Y., Kumemura, M., Ueno, T., Uchiyama, S. et al., Discovery of an S-equol rich food stinky tofu, a traditional fermented soy product in Taiwan. Int. J. Food Sci. Nutr. 2012, 63, 964-970.
32. Goodman-Gruen, D., Kritz-Silverstein, D., Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J. Nutr. 2001, 131, 1202-1206.
33. Nordentoft, I., Jeppesen, P.-B., Hong, J., Abudula, R. et al., Increased insulin sensitivity and changes in the expression profile of key insulin regulatory genes and beta cell transcription factors in diabetic KKAy-mice after feeding with a soy bean protein rich diet high in isoflavone content. J. Agric. Food Chem. 2008, 56, 4377-4385.
34. Berasi, S.-P., Huard, C., Li, D., Shih, H.-H. et al., Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J. Biol. Chem. 2006, 281, 27167-27177.
35. Davies, G.-F., Khandelwal, R.-L., Wu, L., Juurlink, B.-H. et al., Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferators-activated receptor-gamma (PPAR gamma)-independent, antioxidant-related mechanism. Biochem. Pharmacol. 2001, 62, 1071-1079.
36. Park, S.-A., Choi, M.-S., Cho, S.-Y., Seo, J.-S. et al., Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57 BL/KsJ-db/db mice. Life Sci. 2006, 79, 1207-1213.
37. Katsanos, C.-S., Lipid-induced insulin resistance in the liver: role of exercise. Sports Med. 2004, 34, 955-965.
38. Choi, M.-S., Jung, U.-J., Yeo, J., Kim, M.-J. et al., Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab. Res. Rev. 2008, 24, 74-81.
39. Lee, J.-S., Effect of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. Life Sci. 2006, 79, 1578-1584.
40. Merrill, G.-F., Kurth, E.-J., Hardie, D.-G., Winder, W.-W., AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 1997, 273, E1107-E1112.
41. Kemp, B.-E., Mitchelhill, K.-I., Stapleton, D., Michell, B.-J. et al., Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 1999, 24, 22-25.
42. Cederroth, C.-R., Vinciguerra, M., Gjinovci, A., Kühne, F. et al., Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 2008, 57, 1176-1185.
43. Minakawa, M., Kawano, A., Miura, Y., Yagasaki, K., Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic cells. J. Clin. Biochem. Nutr. 2011, 48, 237-244.
44. Son, M. J., Minakawa, M., Miura, Y., Yagasaki, K., Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur. J. Nutr. 2013, 52, 1607-1619.